Taming food-induced immune disorders
Interviewee/Contributor
Poul Sørensen
Organisation
Allero Therapeutics BV
Immunotherapy
The US continues to lead in oncology approvals
Interviewee/Contributor
Bruno Pagliara
Organisation
MedNous
Genmab looks ahead to next phase of growth
Interviewee/Contributor
Jan van de Winkel
Organisation
Genmab A/S
Long-term strategies for immuno-oncology
Interviewee/Contributor
Bruno Pagliara
Organisation
On-kòs Pharma Consulting
Novel immunotherapy arises from collaboration
Interviewee/Contributor
Andrea van Elsas
Organisation
Aduro Biotech Inc
Medigene on a new course
Interviewee/Contributor
Dolores Schendel
Organisation
Medigene AG
Using the accelerator and brake to treat cancer
Interviewee/Contributor
Frédéric Triebel
Organisation
Prima BioMed Ltd
How Pharma is targeting checkpoint inhibitors
Interviewee/Contributor
Bruno Pagliara
Immunotherapies start to transform cancer care
Interviewee/Contributor
Bruno Pagliara
Organisation
On-kòs Pharma Consulting
Bringing exhausted T cells back from the brink
Interviewee/Contributor
Stephen J Turner
Organisation
Biomedical Discovery Institute, Monash University